Author

Martin Farlow

Institutions: Indiana University Health, Indiana University School of Medicine

Observed institutions: Indiana University Health, Indiana University School of Medicine

OpenAlex ID: A5159705030

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

2014 · Rachelle S Doody, Martin Farlow, et al. · PubMed · 56

Identification of genetic modifiers of autosomal dominant Alzheimer's disease: a genome-wide association study

2026 · Maulikkumar Patel, Wei Feng, et al. · The Lancet Neurology · 1

Works count: 2

Citation count: 57

H-index: 1

I10-index: 1